Takeda Pharmaceutical (TSE:4502) Valuation Check As Short Term Weakness Meets Longer Term Returns

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Takeda Pharmaceutical (TSE:4502) is back in focus after recent trading, with the stock closing at ¥5,108 and showing mixed short term moves, including a decline over the past 3 months and over the past month.

See our latest analysis for Takeda Pharmaceutical.

The recent 1 day share price gain of 0.95% contrasts with a weaker 3 month share price return of a 10.87% decline. The 1 year total shareholder return of 25.93% highlights how dividends have supported longer term investors even as shorter term momentum has faded.

If Takeda’s recent moves have you thinking about where else growth or income could come from, it may be worth scanning for other companies using our screener of 7 healthcare AI stocks

With Takeda’s share price softening in recent months, but longer term returns and analyst targets pointing higher than today’s ¥5,108 level, you have to ask: is this a genuine value gap, or is future growth already priced in?

Most Popular Narrative: 15.4% Undervalued

Takeda’s last close at ¥5,108 sits below a widely followed narrative fair value of ¥6,036.87, with that view built around a long earnings recovery story.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda's core growth and launch products to drive top-line and earnings recovery going forward.

Read the complete narrative.

Want to see what sits behind that recovery path and premium future earnings multiple, and how revenue, margin and earnings assumptions fit together over time?

Result: Fair Value of ¥6,036.87 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on generic and biosimilar pressure easing as expected, and on key late stage drugs clearing regulatory and clinical hurdles without major setbacks.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Another View: High P/E Puts The Brakes On The Undervaluation Story

The fair value narrative suggests Takeda is 15.4% undervalued at ¥5,108, but the P/E picture tells a tougher story. At 42.1x earnings, the stock trades well above peers at 19.1x and a fair ratio of 35.6x, which points to less room for error if growth disappoints.

For a closer look at how this valuation gap stacks up against peers and the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.TSE:4502 P/E Ratio as at May 2026

Next Steps

The mix of potential and concern running through this story means it is worth checking the data for yourself and not just relying on headlines, then weighing up the 4 key rewards and 3 important warning signs.

Story Continues

Looking for more investment ideas?

If Takeda has sharpened your focus on valuation, do not stop here. Broaden your watchlist with other stocks that might suit your return and risk goals.

Target income first and foremost by checking out 45 dividend fortresses that aim to combine higher yields with resilient cash flows. Spot potential bargains before the crowd by scanning screener containing 59 high quality undiscovered gems that pair solid fundamentals with relatively low market attention. Prioritise capital preservation while still seeking upside by reviewing 58 resilient stocks with low risk scores that score well on financial strength and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 4502.T.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments